Press-release for stocks for ligand pharmaceuticals incorporated for sny

entities : Ligand pharmaceuticals incorporated symbols : Sny

save search

Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
Published: 2022-12-05 (Crawled : 13:00) - biospace.com/
ABT | News | $107.59 0.49% -0.09% 3.8M

Health Technology

| -0.94% | O: -1.11% H: 0.16% C: -1.38%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| 2.8% | O: -0.1% H: 0.0% C: 0.0%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -5.68% | O: -0.43% H: 1.0% C: -3.66%
pharmaceuticals ceo

Ligand Announces Completion of OmniAb Spin-Off
Published: 2022-11-01 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| 12.16% | O: 7.74% H: 0.17% C: 0.17%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| 7.37% | O: 0.23% H: 0.0% C: 0.0%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -21.81% | O: 0.0% H: 1.5% C: -3.47%

Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-10-26 (Crawled : 12:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| 13.19% | O: 1.89% H: 0.0% C: 0.0%
AHPA 4 | $6.125 -9.26% 4.33%

| -35.59% | O: -5.1% H: 1.72% C: -8.48%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| 13.49% | O: 2.12% H: 0.0% C: 0.0%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -21.49% | O: 0.48% H: 2.13% C: -0.81%
treatment fda approval

Avista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinary General Meeting to Vote on Proposed Business Combination
Published: 2022-10-03 (Crawled : 12:20) - prnewswire.com
AHPA 4 | $6.125 -9.26% 4.33%

| -40.01% | O: 0.39% H: 0.1% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| 20.55% | O: 0.74% H: 0.0% C: 0.0%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -20.42% | O: 0.12% H: 2.95% C: 0.95%
acquisition meeting

Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-08-24 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| 9.06% | O: -4.66% H: 0.0% C: -1.69%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| 13.05% | O: -1.48% H: 0.0% C: 0.0%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -32.54% | O: -0.75% H: 3.45% C: 2.49%
tecvayli treatment approval

Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Aug 02, 2022
Published: 2022-08-02 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -4.43% | O: 3.91% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -5.6% | O: 1.11% H: 0.0% C: 0.0%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -23.6% | O: -0.97% H: 5.07% C: 3.85%
nasdaq grants

Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
Published: 2022-06-29 (Crawled : 22:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -11.97% | O: 0.02% H: 0.0% C: 0.0%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -21.42% | O: -0.63% H: 2.13% C: 2.1%

Ligand to Report First Quarter Financial Results on May 4
Published: 2022-04-19 (Crawled : 22:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -16.15% | O: 0.18% H: 0.0% C: 0.0%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -31.95% | O: 0.87% H: 1.96% C: 1.58%
report results

Ligand to Report Fourth Quarter Financial Results on February 17
Published: 2022-02-09 (Crawled : 20:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -13.36% | O: 2.73% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -13.67% | O: -0.43% H: 0.0% C: 0.0%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -44.45% | O: 1.07% H: 1.67% C: 0.37%
financial results report results

Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
Published: 2021-12-22 (Crawled : 13:30) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -6.63% | O: -0.59% H: 1.12% C: 0.93%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -54.62% | O: 0.73% H: 3.33% C: 2.86%
cejemly treatment ema als approval cel lung cancer china therapy cancer

Ligand and GSK Expand Global Collaboration and License Agreement
Published: 2021-12-21 (Crawled : 22:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -5.5% | O: 0.76% H: 0.67% C: 0.45%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -55.27% | O: -0.12% H: 0.06% C: -1.31%
license collaboration

Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
Published: 2021-10-21 (Crawled : 14:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -5.66% | O: -0.08% H: 0.41% C: 0.41%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -47.85% | O: -0.17% H: 1.8% C: 0.91%
covid collaboration technology

Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
Published: 2021-08-30 (Crawled : 21:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -10.68% | O: 0.25% H: 0.46% C: -0.46%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -40.06% | O: 0.65% H: 5.84% C: 5.28%
treatment china approval

Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Published: 2021-08-16 (Crawled : 20:00) - biospace.com/
TVTX | $5.745 -1.8% -1.83% 1.2M

Health Technology

| -61.89% | O: 34.01% H: 3.74% C: -13.37%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -10.2% | O: 0.17% H: 0.62% C: 0.48%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -35.85% | O: -0.76% H: 2.93% C: 1.17%
ongoing positive results topline nephropathy phase 3

Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms
Published: 2021-07-28 (Crawled : 21:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -10.32% | O: -0.5% H: 1.7% C: 1.4%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -43.09% | O: -0.02% H: 3.36% C: 2.53%
software antibody platform

Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
Published: 2021-07-21 (Crawled : 13:15) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -9.97% | O: -0.06% H: 0.38% C: 0.25%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -44.03% | O: 0.06% H: 2.11% C: 1.35%
JAZZ | $109.685 0.79% 0.78% 380K

Health Technology

| -37.92% | O: -0.22% H: 2.61% C: 1.09%

Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
Published: 2021-07-19 (Crawled : 13:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -10.42% | O: -0.68% H: 0.41% C: -0.31%
LGND | $69.97 2.1% 2.06% 140K

Health Technology

| -42.13% | O: -5.38% H: 8.88% C: 8.3%
disease fda fda approval approval pneumococcal

Ligand to Report Second Quarter Financial Results on July 29, 2021
Published: 2021-07-16 (Crawled : 15:15) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology